Work

Ethical and Practical Issues Associated with Aggregating Databases

Year: 2008
Type: article
Abstract: he goal of "personalized medicine" relies upon defining the genetic variation responsible for disease susceptibility and response to therapy [1].For most common human diseases, the contribution of a single sequence variant to disease susceptibility is typically small, and can only be detected with data from large numbers of people [2].Practically, this necessitates collaboration among investigators who either have DNA and phenotypic information previously collected, or have access to populations from which to recruit participants.It also requires that data be shared among the collaborators.Modern bioinformatics platforms have the capacity to combine datasets and store them for re-analysis.This is scientifically advantageous since it makes possible studies with enhanced validity in a cost-effective fashion.However, this data storage can complicate the already vexing practical, scientific, and ethical issues associated with gene and tissue banks.Research participants' data may have been collected without authorization that meets today's standards for informed consent.Research participants may not have consented to participation in genetics research in general, to inclusion in genetics databases specifically, or to use of their samples in genetic analyses that were unanticipated, unknown, or nonexistent at the time samples were collected [3].Participants who consented to the collection of their data for use in a particular study, or inclusion in a particular database, may not have consented to "secondary uses" of those data for unrelated research, or use by other investigators or third parties [4].There is concern that institutional review boards (IRBs) or similar bodies will not approve of the formation of aggregated databases or will limit the types of studies that can be done with them, even if those studies are believed by others to be appropriate, since there is a lack of consensus about how to deal with re-use of data in this manner.Combined databases can raise other important ethical concerns that are unrelated to the original consent process.For example, they may make it possible for investigators to identify individuals, families, and groups.Such concerns may be exacerbated in settings where there is the possibility of access to data by individuals who are not part of the original research team.For example, the National Institutes of Health (NIH) Data Sharing Policy (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html)requires investigators receiving more than US$500,000 per year to share the final research data.For genome-wide association studies, individual records are to be deposited into dbGaP (Database of Genotypes and Phenotypes) at the National Center for Biotechnology Information.While only aggregate data will be accessible to the public, record-level data will be accessible to other investigators who agree to certain terms regarding confidentiality and data security (http:// grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html).Further, databases developed for different kinds of studies, with different methodologies and conventions for analyzing and reporting results, that are then aggregated, may not be interoperable, leading to flawed analyses.Finally, The Guidelines and Guidance section contains advice on conducting and reporting medical research.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $6,460
OpenAlex ID: W2045970386
FWCI: 3.511
Cites: 22
Cited by: 32
Related to: 9
Parts: 1